PrEP TMC278LA: Safety, Tolerability and Pharmacokinetics of TMC278LA in HIV Negative Volunteers.
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2010
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 13 Aug 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.